← back to search

Richard J. Jones

University College London · US
Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, and Chronic Myeloid Leukemia Treatments.
h-index
83
citations
24,612
works
494
NIH funding
primary concept
Medicine
email

Recent publications

Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide
Transplantation and Cellular Therapy 2026cited by 3position: contributordoi
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with <i>FLT3-ITD</i>–mutated AML
Blood 2025cited by 30position: middledoi
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703
Blood Advances 2025cited by 8position: middledoi
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703
Journal of Clinical Oncology 2025cited by 6position: middledoi
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>
Journal of Clinical Oncology 2024cited by 177position: middledoi
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis
New England Journal of Medicine 2023cited by 525position: middledoi
Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration
Haematologica 2023cited by 13position: middledoi
Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703
Blood 2022cited by 52position: middledoi
Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT
Blood Advances 2022cited by 37position: middledoi
The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia.
2022cited by 21position: contributordoi
Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning
Blood 2021cited by 98position: middledoi
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial
Blood 2020cited by 209position: middledoi
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide
Blood Advances 2020cited by 148position: middledoi
Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study
The Lancet HIV 2020cited by 48position: middledoi
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
The Lancet Haematology 2019cited by 279position: middledoi
Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial
The Lancet Haematology 2019cited by 152position: middledoi
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide
Haematologica 2016cited by 187position: middledoi
Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia
Biology of Blood and Marrow Transplantation 2016cited by 132position: middledoi
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
Blood 2015cited by 299position: middledoi
A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality
Biology of Blood and Marrow Transplantation 2015cited by 276position: middledoi
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults
Journal of Clinical Oncology 2015cited by 238position: lastdoi
Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma
Science Translational Medicine 2015cited by 126position: middledoi
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS
Blood 2014cited by 198position: middledoi
Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation Cyclophosphamide
Science Translational Medicine 2013cited by 356position: middledoi
Regulation of human hematopoietic stem cell self-renewal by the microenvironment’s control of retinoic acid signaling
Proceedings of the National Academy of Sciences 2013cited by 139position: lastdoi
Partially Mismatched Transplantation and Human Leukocyte Antigen Donor-Specific Antibodies
Biology of Blood and Marrow Transplantation 2013cited by 127position: middledoi
HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease
Blood 2012cited by 441position: middledoi
A clinically relevant population of leukemic CD34+CD38− cells in acute myeloid leukemia
Blood 2012cited by 217position: lastdoi
HIV-1 DNA Is Detected in Bone Marrow Populations Containing CD4+ T Cells but Is not Found in Purified CD34+ Hematopoietic Progenitor Cells in Most Patients on Antiretroviral Therapy
The Journal of Infectious Diseases 2012cited by 117position: middledoi

Grants

Nuclear Physics Research and Education with GlueX
NSF2514864$299,9722025–2028PIRePORTER
Research and Education with GlueX
NSF2209480$416,9932022–2026PIRePORTER
CC* Compute: Shared Computing Infrastructure for Large-scale Science Problems
NSF1925716$400,0002019–2022PIRePORTER
Research and Education with GlueX
NSF1812415$363,0002018–2022PIRePORTER
Research and Education with GlueX
NSF1508238$405,0002015–2019PIRePORTER
Research and Education with GlueX
NSF1207857$375,0002012–2015PIRePORTER
Nuclear Physics Research and Education with GlueX
NSF0901016$335,0612009–2013PIRePORTER
US-Japan Nuclear Physics Workshop
NSF0837305$19,8002009–2011PIRePORTER
Collaborative Research: Open Access Amplitude Analysis on a Grid
NSF0653536$332,2652007–2012PIRePORTER
Research Program in Intermediate Energy Physics
NSF0402151$85,2782004–2006PIRePORTER
Research Program in Intermediate Energy Physics
NSF0303512$74,9822003–2004PIRePORTER
Co-editor of "NSF Highlights" Column Published in The Journal of Chemical Education
NSF0226489$10,8902002–2005PIRePORTER
Research Program in Experimental Intermediate Energy Physics
NSF0072416$252,1862000–2003PIRePORTER
Co-editor of "NSF Highlights" Column in The Journal of Chemical Education
NSF9909132$12,1921999–2002PIRePORTER
Instrumentation Workshop for Two-Year College Chemistry Faculty
NSF9752787$185,0001998–2000PIRePORTER
Instrumentation Workshop for Two-Year College Chemistry Faculty
NSF9653389$84,5001997–1998PIRePORTER
Neuroendocrine Control of Brain Aging
NSF9603622$81,5131997–2000PIRePORTER
1996 Presidential Awardee
NSF9708763$7,5001997–2000PIRePORTER
Dissertation Research: The Effects of Cortisol on Home- Steam Water Imprinting and Recall in Kokanee Salmon
NSF9701027$4,8491997–1998PIRePORTER
Instrumentation Workshops for Two-Year College Chemistry Faculty
NSF9455063$275,0001995–1997PIRePORTER
Instrumentation Workshops for Two-Year College Chemistry Faculty
NSF9154191$170,0661992–1994PIRePORTER
New Directions in Metal Phosphido and Arsenido Chemistry
NSF8818984$203,8001989–1992PIRePORTER
Introduction of NMR into Organic Chemistry Laboratories
NSF8950927$26,0151989–1991PIRePORTER
Bilateral NSF-SERC Main Group Chemistry Workshop, Imperial College, London, England, August 9-12, 1989
NSF8913924$16,3351989–1990PIRePORTER
The Role of U.S. Migration in the Economic Base of Rural Mexico
NSF8619504$74,4711987–1989PIRePORTER

Frequent collaborators

Ephraim J. Fuchs · U-M Rogel Cancer Center9 papers (2012–2020)Robert A. Brodsky · Sidney Kimmel Cancer Center7 papers (2012–2020)Javier Bolaños‐Meade · Comprehensive Blood & Cancer Center7 papers (2012–2020)Leo Luznik · U-M Rogel Cancer Center7 papers (2012–2021)Kenneth R. Cooke · Murdoch Children's Research Institute6 papers (2016–2026)Richard F. Ambinder · University of Baltimore6 papers (2012–2020)Carol Ann Huff · Johns Hopkins University5 papers (2014–2020)Douglas E. Gladstone · Northwell Health5 papers (2013–2020)Heather J. Symons · Pediatric Oncology Group5 papers (2016–2021)Ivan Borrello · Johns Hopkins Medicine5 papers (2014–2020)Amy E. DeZern · U-M Rogel Cancer Center5 papers (2014–2026)Christopher G. Kanakry · National Institutes of Health4 papers (2013–2021)Lode J. Swinnen · Tokyo National Hospital4 papers (2014–2020)Gary L. Rosner · United States Food and Drug Administration4 papers (2014–2020) · 3 papers (2012–2013)Marianna Zahurak · Johns Hopkins University3 papers (2013–2020)Yvette L. Kasamon · Center for Drug Evaluation and Research3 papers (2013–2016)Shannon R. McCurdy · Pacific Biosciences (United States)3 papers (2016–2023)Mark J. Levis · University of Turin3 papers (2012–2016)B. Douglas Smith · University of Rochester Medical Center3 papers (2012–2016)